Boryung Pharm concludes supply agreement of KRW 85.4 billion worth finished drugs with Sandoz
On the 20th, Boryung Pharm officially announced the exclusive license and product supply agreement of KRW 85.4 billion to 6 East Asian countries with Sandoz AG, a subsidiary of Novartis Group.
According to Boryung Pharm(CEO Tae-hong Choi) the company established an export agreement of ‘Cilnidipi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
